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Abstract
Cachexia is a multifactorial syndrome characterized by profound involuntary weight loss, fat
depletion, skeletal muscle wasting, and asthenia; all symptoms are not entirely attributable
to inadequate nutritional intake. Adipose tissue and skeletal muscle loss during cancer
cachexia development has been described systematically. The former was proposed to
precede and be more rapid than the latter, which presents a means for the early detection of
cachexia in cancer patients. Recently, pioglitazone (PGZ) was proposed to exhibit anti-
cancer properties, including a reduction in insulin resistance and adipose tissue loss; never-
theless, few studies have evaluated its effect on survival. For greater insight into a potential
anti-cachectic effect due to PGZ, 8-week-old male Wistar rats were subcutaneously inocu-
lated with 1 mL (2×107) of Walker 256 tumor cells. The animals were randomly assigned to
two experimental groups: TC (tumor + saline-control) and TP5 (tumor + PGZ/5 mg). Body
weight, food ingestion and tumor growth were measured at baseline and after removal of
tumor on days 7, 14 and 26. Samples from different visceral adipose tissue (AT) depots
were collected on days 7 and 14 and stored at -80o C (5 to 7 animals per day/group). The
PGZ treatment showed an increase in the survival average of 27.3% (P< 0.01) when com-
pared to TC. It was also associated with enhanced body mass preservation (40.7 and
56.3%, p< 0.01) on day 14 and 26 compared with the TC group. The treatment also re-
duced the final tumor mass (53.4%, p<0.05) and anorexia compared with the TC group dur-
ing late-stage cachexia. The retroperitoneal AT (RPAT) mass was preserved on day 7
compared with the TC group during the same experimental period. Such effect also demon-
strates inverse relationship with tumor growth, on day 14. Gene expression of PPAR-γ,
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adiponectin, LPL and C/EBP-α from cachectic rats was upregulated after PGZ. Glucose up-
take from adipocyte cells (RPAT) was entirely re-established due to PGZ treatment. Taken
together, the results demonstrate beneficial effects of PGZ treatment at both the early and
final stages of cachexia.
Introduction
Cachexia is a multifactorial syndrome characterized by profound involuntary weight loss, fat
depletion, skeletal muscle wasting, and asthenia; all symptoms are not solely attributable to in-
adequate nutritional intake [1,2]. Cachexia is implicated in up to 40% of all cancer deaths and
is directly responsible for an impaired quality of life and increased health care costs [3]. Clinical
treatments to overcome cachexia and its outcomes are currently unavailable.
Loss of both adipose tissue and skeletal muscle mass during cancer cachexia development
has been well-characterized and systematically described [4,5]. The former is proposed to pre-
cede and occur more rapidly than the latter [6]. For this aspect, several factors have been pro-
posed to cause adipose tissue loss and metabolic “chaos”, such as increased lipid mobilization
due to enhanced adipocyte lipolysis [5,7], reduced lipogenesis due to decreased lipoprotein li-
pase activity [8], down-regulation of key adipogenic factors [9,10] and insulin resistance [11].
We previously showed that some of these changes occur at a very early stage during cancer ca-
chexia development, even before the clinical signs of cachexia appear in tumor-bearing rats.
The rats exhibited substantially reduced gene transcription and protein expression of crucial
adipogenic proteins, such as PPAR-γ, C/EBPα and perilipin in visceral depots during the early
stages of cachexia. The disruption was followed by adipocyte morphological modifications,
which became progressively more evident during the late disease stages [10].
Thiazolidinedione (TZD) encompasses a class of drugs that activate peroxisome proliferator
activated receptor gamma (PPARγ), which is a key transcription factor that induces insulin-
sensitive genes and is targeted in Type II diabetes mellitus treatment [12,13]. In recent studies,
this drug class exhibited anti-cancer properties; Troglitazone (TGZ) inhibits colorectal, breast,
and prostate cancer cell growth [14,15], and pioglitazone (PGZ) arrests the cell cycle and in-
duces primary liposarcoma cell differentiation [16,17]. A reduced risk of lung cancer has also
been reported [18]. Despite these encouraging results, associated toxicities inhibit clinical ther-
apeutic potential [19].
In addition to its anti-cancer effect, in recent studies with cachectic mice bearing colon-26
tumors, rosiglitazone treatment improved insulin sensitivity and attenuated skeletal muscle
protein degradation during early cachexia [11,20]. However, during the experimental period,
the tumor mass was unaffected by the treatment. Furthermore, the final body weight was not
correlated to tumor size, which indicates that the effects of rosiglitazone in attenuating cachexia
did not depend on tumor size. On the other hand, despite a previous study that showed an ini-
tial anti-cachectic effect, cachexia development was only evaluated over a 14-day period, which
may be an insufficient timeframe for evaluating its effectiveness on body weight loss and tumor
growth. In addition, no PGZ dose-response curves are available for cachexia markers.
For greater insight into a potential anti-cachexia effect from PGZ during cancer cachexia
development, we analyzed the RPAT and MEAT depots at different time points following
tumor injection and PGZ treatment. Herein, we present the following results: 1) a TZD dose-
dependent response that affects survival; 2) body weight and tumor mass evolution during ca-
chexia progress; and 3) insulin-induced glucose uptake from isolated adipocytes at the early
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and final stages of cachexia. Considering each factor, the results show that both body and
tumor mass are preserved during the final cachexia stages, which correlates with the PGZ dose-
concentration. In addition, the results suggest that the retroperitoneal adipose pad (RPAT),
which is most affected in Walker tumor-bearing animals, is more responsive to PGZ when the
treatment begins upon onset of cachexia.
Material and Methods
Animals
Male adult Wistar rats (160–250 g), obtained from the Institute of Biomedical Sciences, Uni-
versity of São Paulo, were maintained in metabolic cages, in a 12 h light: 12 h dark cycle (lights
on at 07:00 h), under controlled temperature conditions (23±1°C), receiving water and food
(NuvilabCR1-Nuvital, Curitiba, Paraná, Brazil), ad libitum. The Ethical Committee for Animal
Research from the University of Mogi das Cruzes approved all the adopted procedures, which
were carried out in accordance with the ethical principles stated by the Brazilian College of An-
imal Experimentation (BCAA)—Protocol n. 008/2011.
Experimental Design
Study 1. In order to determine an initial dosage of PGZ capable of inducing modification
on survival rate, a pilot study was conducted. Therefore, we tested four doses of the drug ad-
justed to rat body weight (mg / kg body weight / day) at the following concentrations; 0 (NaCl
0.9%), 5, 10, 20 and 40 mg/kg/day, which was administered orally by intragastric gavage. For
all groups, PGZ or saline administration were carried out throughout the same vehicle solution,
sodium chloride 0.9% plus 0,1% DMSO. The treatment was administered daily from one week
before inoculation of the tumor cells up to the 28th day. The experimental groups were divided
according to dose-treatment: TC (tumor + saline-control), TP5 (tumor + PGZ/5mg), TP10 (tu-
mour + PGZ/10mg), TP20 (tumor + PGZ/20mg), TP40 (tumor + PGZ/40mg).
Weight and food intake were assessed daily, always in the afternoon. Walker 256 tumor
cells (2 x107 cells) were injected subcutaneously (s.c.) into the right flank of the animals
[21,22]. Control rats received saline injections on the same day of tumor inoculation. Cachexia
is usually observed in rats bearing Walker 256 tumors after 10–15 days [23]. To evaluate the ef-
fect of PGZ treatment during cancer cachexia progression, the experiments were carried out as
a time course study. The impact of tumor growth and development of cachexia on animal wel-
fare were considered, with appropriate measures to monitor and alleviate suffering implemen-
tation. Rats were euthanized by overdose of anesthetic (thiopental sodium) injection at 28
days, or when weight loss reached 35%, or tumor size reached 65 mm, whichever
occurred first.
Study 2. After the initial characterization considering the lowest dose capable of inducing
increased animal survival, male Wistar rats were randomly assigned to two experimental
groups, as follows; TC (tumor + saline-control) and TP5 (tumor + PGZ/5mg). PGZ suspension
was prepared as described (Study 1). Walker 256 tumor cells (2x107 cells) were subcutaneously
injected into the right flank of the animals [21,22]. Control rats received saline injections on
the same day of tumor cells inoculation. To evaluate PGZ treatment (5 mg) effect during cancer
cachexia progression, in particular considering clinical signs (body weight, food ingestion and
tumor growth) the experiments were carried out as a time course study, considering three dif-
ferent experimental time points (7, 14 or 26 days post-injection). Such periods were chosen
considering identification of the early and end points of the cachexia trajectory [10]. To evalu-
ate the impact of cachexia in WAT depots, experiments were carried out at two different
experimental times (7 and 14 days post-injection). Rats were euthanized on days 7, 14 or
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26 post-injection (seven to ten animals on each time point) with thiopental sodium (50 μg/g
body wt) injection followed by decapitation after 12 h fasting. For the biochemical analysis, an
additional control group was included to access baseline values.
Blood sampling and adipose tissue collection
Trunk blood was collected after decapitation into 15 ml conical tubes containing EDTA (1.8
mg/ml of blood), centrifuged at 500 g and 4°C for 10 min, and stored at -80°C. Epididymal
(EAT), retroperitoneal (RPAT) and mesenteric (MEAT) adipose tissue depots (after careful re-
moval of adjacent lymph nodes) were removed, weighed, snap frozen in liquid nitrogen and
stored at -80°C.
General Biochemical parameters
The concentration of triacylglycerol, glucose, albumin, and the activity of liver enzymes: aspar-
tate aminotransferase (AST), alanine aminotransferase (ALT), and total protein were measured
by commercial kits (Labtest, Brazil). For general biochemical analysis, it was used a control
baseline group, matched by age, with neither tumor cells, neither saline inoculation, nor
PGZ treatment.
Adipocyte isolation
Adipocytes were isolated by collagenase treatment of adipose tissue as previously described
[24]. The cell suspensions (40% final concentration corresponding to 106 cells/ml) were incu-
bated in a 37°C water bath for 30 min before initiating the biological tests as detailed below.
Adipocyte viability and number were determined as previously described [25].
RT-qPCR
Total RNA was isolated from isolated adipocytes from the RPAT samples employing Trizol.
(Invitrogen, Carlsbad, CA, USA) following the manufacturer’s recommendations. The concen-
tration of the RNA extract was determined using the Synergy H1 Multi-Mode Microplate
Reader (BioTek Instruments, Winooski, VT, USA) with the Take3 microdrop addition at an
absorbance of 260 nm (A260) and 280 nm (A280) in 10 mM Tris-Cl at pH 7.5. The estimative of
RNA purity was determined by calculating the ratio between the two readings (A260/A280).
RNA integrity was checked on a 2% agarose gel containing SYBR Safe DNA gel stain (Invitro-
gen Corporation, Carlsbad, CA, USA). (Invitrogen Corporation, Carlsbad, CA, USA). RT-PCR
was performed on the total RNA (4 μg), which was employed for first-strand synthesis of
cDNA using a commercially available kit (Ambion, Austin, TX, USA). The reaction mixture
was stored at -80°C until the PCR step. Primer sets for rat PPAR-γ (NM 001145366.1 sense
5`-CTG CCT ATG AGC ACT TCA CAA-3 and antisense 5`-CGT TGG CTGCGT TCA TGT
CGT AAT-3`), C/EBP-α (NM 012524.2: sense, 5`-GAA GTC GGT GGA TAA GAA CAG C-
3`and antisense, 5`-GGT CAT TGT CAC TGG TCA ACT C-3`), SREBP-1c (XM 213329.5:
sense, 5`-AGG GAG TTC TCA GAT GCT CTT G-3 and antisense, 5`-CAT GCT GGA ACT
GAC AGA GAA G-3`), adiponectin (NM 144744.3: sense, 5`-ATC CTG CCC AGT CAT GAA
GGG ATT-3`and antisense, 5`-TGC CAT CCA ACC TGC ACA AGT TTC-3`), LPL (NM
012598.2: sense, 5`-GAG TTT GGC TCC AGA GTT TGA-3`and antisense, 5`-GTG TCC TCA
GCT GTG TCT TCA-3`), FAS (NM 139194.2: sense, 5`-CAT TTT GCT GTC AAC CGT GT-
3`and antisense, 5`-CGT GTA CTC CTC CCC TTC TG-3`), were designed using Primer Ex-
press software v2.0 (Applied Biosystems, Foster City, CA, USA). The results for mRNA con-
centrations are expressed as a ratio over 18S-ribosomal ribonucleic acid (rRNA), which was
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amplified as a housekeeping gene using the following primers: 18S rRNA (M11188.1 sense
5`-TCA GCT TTG CAA CCA TAC TCC -3`, and antisense 5`-GAC CAT AAA CGA TGC CGA
CT-3`). For each sample, PCR was performed in duplicate in a 25-μL reaction volume of 5–20
ng of cDNA, 12.5 μL Syber Green Master Mix (Applied Biosystems), and 200–600 nM of each
primer. PCR analyses were carried out using the following cycle parameters: 50°C for 2 min,
95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Fluorescence was
quantified and analyses of amplification plots were performed with the ABI Prism 7700 Se-
quence Detector System (Applied Biosystems, Foster City, CA). All samples were normalized
to the 18S values and the results were expressed as fold changes of Ct values relative to controls
adopting the 2–DDCt formula. 18S was adopted as a reference gene, since we have experimental-
ly determined that there were no statistically significant differences of its Ct values between
control and different times of the tumor-bearing groups (both P<0.05, three experiments).
[3H]-2DG uptake assay
Deoxy-D[2,6 3H]glucose uptake (2DGU) in isolated adipocytes. 2DGU experiments
were performed as described elsewhere [26] with some modifications. Briefly, aliquots (40 μL)
of isolated adipocytes (40–50% cell suspension) were transferred to 2-ml plastic test tubes with
or without insulin (2.5 nmol/L) diluted in EHB buffer 2 (pH 7.4), and the cells were incubated
for 15 min in a water bath at 37°C. At the end of the incubation period, a 10-μl aliquot of
2-deoxy-D-[3H]-glucose was added (3H-2DG, 0.4 mmol/l final concentration and 0.05 μCi/
tube) and the uptake reaction was allowed to occur for exactly 3 min. The reaction was inter-
rupted by adding 250 μL of ice-cold phloretin (0.6 mmol/l in EHB and DMSO 0.05%). Next,
200 μL of this last mixture were transferred to microfuge tubes (450-μl capacity), layered with
200 μL of silicone oil (density = 0.963 mg/ml) and centrifuged (Microfuge E, Beckman Instru-
ments, Palo Alto, CA) for 10 s at 11.000 g. The cell pellet on top of the oil layer was transferred
to 4-mL vials containing 2.5 mL of scintillation cocktail (EcoLume, ICN Pharmaceuticals,
Costa Mesa, CA, USA), and the trapped radioactivity was measured in a liquid scintillation
counter (MicroBetaTriLux 1450 LSC & luminescence Counter, PerkinElmer, USA). Unspecific
3H-2DG radiolabel trapping was determined in a parallel tube already prepared with 250 μl of
ice-cold phloretin to stop transport reaction before adding the tracer. This value was dis-
counted from the total trapping, and the resultant specific uptake was recalculated and express-
ed as picomoles (pmol) per square centimeter of cell surface area.
Statistical analysis
Data are expressed as mean values ± S.E.M. Differences between times of tumor cell injection
(cachexia progression: days 0, 7, 14 and 26) were analyzed by one-way ANOVA followed by
Bonferroni’s post-hoc comparisons tests using GRAPHPAD PRISM software for Macintosh,
version 6.0 (GraphPad, San Diego, CA, USA). The differences between qualitative variables on
days 7 and 14 against control (matched by age) were determined by the unpaired form of the
Student’s t-test. Kaplan-Meier survival test was performed to evaluate animal survival, using
the same software. We calculated the correlation coefficient between the measures employing
the nonparametric Spearman correlation statistic (r) and the correlation values were calculated
with 2-tailed significance. Glucose transport (2DGU) studies were analyzed with one-way
ANOVA followed by Bonferroni’s post-hoc comparisons. P<0.05 was considered significant
for all statistical tests.
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Results
Study 1
Determining the most efficient PZD dosage. To evaluate the most efficient PGZ dosage
for prolonging the survival of tumor-bearing rats, we tested four different doses of the drug
normalized by animal body weight, administered daily: 5, 10, 20 and 40 mg/kg/day (Study 1).
During the period of treatment (28 days), the first death occurred in an animal of the control
group (TC), on day 17 after the inoculation of tumor cells. At the other extreme of the experi-
ment, 36.3% of animals treated with 5 mg of PGZ (TP5) were still alive on day 28 of the experi-
ment. The rat’s life span is shown in Fig. 1.
The animals in TP5 group showed a survival average of 27 days. This represents an increase
of 27.3% (P< 0.01) when compared to TC, which showed a survival median of 21 days. In the
other groups survival was inversely correlated with dosage, 25 (TP10), 23 (TP10) and 22.5
(TP40) days—no difference to the control group (TC). We thereafter preceded to the second
phase of the study, adopting the minimal dose to affecting survival, 5 mg/kg/day (Study 2).
Characterization of Total Body Mass, tumor growth and food intake in Rats. As body
weight loss is the hallmark of cachexia, this parameter was observed daily along the entire ex-
perimental period, comprising 26 days, as shown in Fig. 2.
This is an important parameter, enabling classification of cachexia stages. Body weight loss
had to be greater than 5% of total body mass [1] in order to characterize the cachectic state.
TP5 group showed a slighter reduction of the percentage of body mass of 4.5% (day 14) and
5.9% (day 26, p< 0.05 for both), compared to the initial experimental period (day 0). TC
Fig 1. Survival of tumor-bearing animals during PGZ treatment period. To evaluate dose-response drug effect, animals were treated with four doses of
PGZ normalized by rat’s body weight, which were administered daily: 5, 10, 20 and 40 mg/kg/day. Plots of Kaplan-Mayer product limit estimates of survival of
a group of tumor-bearing animals receiving PGZ therapy during 26 days, # p<0.05 vs. TC.
doi:10.1371/journal.pone.0122660.g001
Anti-Cachectic Effect of Pioglitazone
PLOS ONE | DOI:10.1371/journal.pone.0122660 March 25, 2015 6 / 16
showed a reduction of about 11.3% on day 14 and 26.9% on day 26 (P<0.01 for both), being
that the greater period of body mass reduction when comparing to TP5 group (40.7, day 14
and 56.3%, for day 26, p<0.01), during the same experimental period (Fig. 2A and B). Anoth-
er important cachexia-associated symptom is anorexia. In our experimental model of
cachexia-induced by Walker 256 tumor-bearing rats, diminished appetite could be detected
between the 10th and 14th day after cells inoculation [10] (Fig. 2C). The animals of both
groups (TC and TP5) presented a reduction of food intake beginning on day 13 (39% and
38%, p<0.05 respectively), as compared to the initial experimental period. However, from day
23, PGZ treatment was able to attenuate anorexia, as TP5 showed the reduction in food intake
of 38% (P<0.01), while in TC showed a decrease of 64% (P<0.001), both measured on the
26th day after tumor cells inoculation (Fig. 2C). We also measured tumor mass on days 7, 14,
and 26 (Fig. 2D). The tumor was dissected and weighed on days 7, 14 and 26 post-injection.
No significant difference was detected on days 7 and 14, considering the relative weight and
treatment among rats. On day 26 there was a reduction of tumor growth in TP5 (53.4%,
p<0.01), as compared to TC (Fig. 2D).
Fig 2. Body weight and food intake for different time points along the progression of cachexia.Rats were inoculated with Walker 256 tumor cells
(2×107 cells) or vehicle and treated daily with 5 mg of PGZ (TP5) or PBS (TC) during 26 days. (A) Body weight was measured on days 4, 7, 14 and 26 and (B)
Relative body weight loss on days 7, 14 and 26-post tumor cells injection. (C) Food intake was measured daily throughout the study and (D) Tumor mass was
measured on days 7, 14 and 26-post tumor cells inoculation. * p<0.05, one-way ANOVA followed by Bonferroni’s post-hoc (time from day 0), and # P<0.05
vs. TC.
doi:10.1371/journal.pone.0122660.g002
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Study 2
Characterization of early PGZ effect on AT mass during cachexia. After euthanasia, the
tissues were collected from retroperitoneal (RPAT) and mesenteric (MEAT) fat depots and
then weighed on the 7th and 14th days after inoculation of tumor cells, to evaluate the treatment
effect on the early signs of cachexia (day 7) and day 14, when the clinical signs of cachexia are
already established (Fig. 3).
RPAT from TP5 was preserved on day 7, showing higher values (25.5%, p<0.05) when
compared to TC in the same experimental period. On the 14th day there was no difference be-
tween TC and TP5. In addition, there was no difference between these groups regarding
MEAT during the same time span (Fig. 3A and C). After we detected a transient and preco-
cious preservation of RPAT mass, we evaluated a possible correlation considering PGZ effect
on RPAT mass (day 7) and reduced tumor mass growth, found in TP5 on day 14. A negative
correlation was present in relation on higher RPAT mass and lower tumor growth (r = -0.7857,
p<0.05) (Fig. 3B). To gain additional insight regarding the PGZ effect in the early stage of ca-
chexia, we examined, in isolated adipocytes from RAPT depots, the expression of genes regu-
lated by PPAR agonists, such PPAR-γ, Adiponectin and lipoprotein lipase (LPL), in RPAT
from cachectic rats. We also examined major transcription factors involved in fat cell
Fig 3. Visceral adipose tissue mass during the progression of cachexia.Rats were inoculated with
Walker 256 tumor cells (2×107 cells) or vehicle and treated daily with 5 mg of PGZ (TP5) or PBS (TC) during
14 days. (A) RPAT and (C) MEAT tissues from tumor-bearing rats were removed and weighed on day 7 and
day 14. (B) Spearman correlation between relative RPATmass on day 7 (early-stage) and tumor growth on
day 14 (cachexia-stage), from TP5. (D) Real-time PCR analysis of RNA isolated from RPAT (isolated
adipocytes) in the 7th on day after tumor cell inoculation. mRNA levels of target genes were normalized to
18S. Values are mean ± s.e.m. for five to seven animals per group. RPAT-retroperitoneal adipose tissue;
MEAT-Mesenteric adipose tissue. #p<0.05 vs. TC.
doi:10.1371/journal.pone.0122660.g003
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formation and maturation, C/EBP-α, SREBP-1c and fat acid synthase (FAS) (Fig. 3D). Gene
expression of PPAR-γ, adiponectin and LPL from TP5 adipocytes showed higher levels on day
7, increasing 48.5% (p<0.01), 1.1 and 1.2-fold (p<0.001, for both), respectively, when com-
pared with TC samples. C/EBP-α expression was also increased after PGZ treatment, showing
1.2-fold increase, when compared with TC, on day 7. SREBP-1c and FAS gene expression was
not affected by the treatment.
Biochemical Tests. Plasma and serum biochemical parameters of rats treated with PGZ
(TP5), vehicle solution (TC) and of the control group were determined on days 7 and 14 after
inoculation of tumor cells (Table 1).
The biochemical profile of animals, either treated with the drug (TP5) or with vehicle (TC)
showed significant alteration in the following parameters. Cachexia-induced hypoglycemia was
detected in TC both on day 7 and 14 (51.3 and 58.4%, respectively), in comparison to the con-
trol group. PGZ treatment, however, attenuated the decrease of fasting blood glucose levels by
12.0% (p<0.01), when compared with TC, on day 7. Treatment (TP5) showed to keep attenua-
tion effect of hypoglycemia induced by the presence of the tumor, and one such effect was even
more pronounced (25.1%, p<0.001) compared to TC, on day 14. Circulating TAG levels
showed no alteration on day 7 for both groups (TP5 and TC), while a still higher concentration
on day 14 (2.3 and 1.8-fold, respectively, p<0.001) in relation to control was found. Addition-
ally, the hepatic enzymes evaluated were also changed. AST displayed a gradual increase in
TP5 in relation to the control group, 1.2-fold on day 7 and 3.9-fold on day 14 (p<0.001, respec-
tively). For TC, the increase was of 14.1% on day 7 and 11.6% on day 14 (p<0.01, respectively).
On day 14, ALT also showed a marked increase in TP5 when compared to the control group
(49.5%, p<0.05). Albuminemia was lower in TP5 and TC on day 7 (34.4%, p<0.05), when
compared to the control group. On day 14, the albumin levels were 36.8%, (p<0.05) lower in
TP5 and 26.5% (p<0.05) in TC, compared to the control group on the same day.
(3H)-2DG uptake in isolated adipocytes. In the attempt to evaluate the interaction be-
tween cachexia and PGZ treatment on cell sensitivity to insulin, a glucose uptake test was done
using isolated adipose cells from RPAT depot. This AT depot was chosen considering that it is
the most affected by the syndrome. We evaluated this parameter on day 7 after the inoculation
of tumor cells, since this was the period in which the treatment efficiently inhibited the reduc-
tion in RPAT mass induced by cachexia. Cells were stimulated by a gradient of increasing in-
sulin concentration (0, 2.5 e 10 nM). The results express tracer flow through the cell surface
area (Fig. 4).
Table 1. Biochemical parameters from tumor-bearing animals during PGZ treatment.
day 7 day 14
Biochemical parameters Control TP5 TC TP5 TC
Glucose (mg/L) 172 ± 3.8 105 ± 4.8 &# 84 ± 6.0& 115 ± 5.0&#* 72 ± 5.3&
TAG (mg/dL) 64 ± 5.6 71 ± 3.9 76 ± 1.5 211 ± 14&#* 180 ± 3.0&#
AST (U/mL) 6.2 ± 2.2 14 ± 1.7& 15 ± 2.7& 31 ± 3.1&#* 13 ± 1.1&
ALT (U/mL) 7.4 ± 3.3 6.1 ± 2.7 6.3 ± 3.7 16 ± 6.5& 11 ± 6.2
Albumin (g/dL) 2.9 ± 0.1 1.9 ± 0.1& 1.9 ± 0.1& 1.8 ± 0.1& 2.1 ± 0.1&
Values are mean ±s.e.m. for ﬁve to seven animals per group.
* p<0.05, one-way ANOVA followed by Bonferroni’s post-hoc (day 7 vs. 14)
# P<0.05 vs. TC,
& P<0.01 vs. Baseline Control.
doi:10.1371/journal.pone.0122660.t001
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TP5 cells showed higher 2DG uptake (93.2%, p<0.005) when stimulated with 2.5 nM of in-
sulin, compared with TC, on day 7. When stimulated with 10 nM of insulin, in the same exper-
imental period, adipocytes from TP5 also showed higher 2DG uptake (57.1%, p<0.01)
compared with TC. Treatment with TP5 totally reverted the effect of cachexia on 2DG uptake
by RPAT adipocytes, that showed no response to insulin ranging from basal to maximal (10
nM) stimulation.
Discussion
We previously demonstrated [10] that, even before classical cachexia symptoms appear, AT
mass reduction, which occurs before lean mass loss, may be associated with the down-
regulation of adipogenic and lipogenic genes during the early stages of the disease. In addition,
several studies have recognized the importance of triglyceride hydrolysis as a major metabolic
Fig 4. 2-Deoxy-D[2,6 3H]glucose uptake assay.Rats were inoculated with Walker 256 tumor cells (2×107 cells) or vehicle and treated daily with 5 mg of
PGZ (TP5) or PBS (TC) during 7 days. Isolated adipocytes from RPAT tissues were stimulated with 0 (basal), 2.5 and 10 (maximal) nmol/cm2 of cell surface
area. RPAT-retroperitoneal adipose tissue; * p<0.05, one-way ANOVA followed by Bonferroni’s post-hoc (time from day 0), # P<0.05 vs. TC, and & P<0.05
vs. Baseline Control.
doi:10.1371/journal.pone.0122660.g004
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pathway involved in cancer cachexia initiation and/or progression [5,27]. Thus, considering
the well-described adipogenic and lipogenic effect of PGZ treatment, we initially tested a hy-
pothesis that pharmacological intervention with PGZ prevents AT loss, at least during the
early stages of cachexia. Consequently, cancer cachexia outcome improves, suggesting this as a
possible clinical tool for improving quality of life in patients who develop the syndrome. The
foremost finding of the present study is that PGZ prolongs survival and preserves visceral fat,
notably in the RPAT depot, mainly during the early phases of the disease (pre-cachexia). Body
mass loss and tumor growth were also attenuated when cachexia signs were present (late-stage
to refractory cachexia). Additionally, transitive and early preservation of RPAT mass seems re-
lated with the preservation of insulin-stimulated glucose-uptake mechanisms, which is a direct
effect of PGZ treatment.
4.1. Determining the ideal dosage and main effects on the clinical signs
of cachexia
The literature includes many collateral effects associated with the use of TZDs. The most com-
monly described effect is hepatotoxicity, which is related to the dose and type of TZD. None-
theless, changes such as retention of fluid, cardiac hypertrophy, hemodilution, anemia,
retinopathy, neuropathy, nephropathy, hyperlipidemia, hypertension, and increased total body
mass have also been described [28–31]. Both the beneficial and collateral effects, such as the
TZD effects, seem directly linked to the dose [32]. To minimize the side effects and simulta-
neously increase the beneficial metabolic effects of AT, the first step of our study was to deter-
mine the appropriate PGZ dose. We found that a 5 mg dose over a 26-day period was most
efficient for both increasing animal survival and preventing total body mass loss, as compared
with larger doses [11,20]. However, no information is available on the collateral effects and/or
survival associated with rosiglitazone treatment. In particular, PGZ was used due to fewer re-
ported side-effects and a greater lipogenic action, compared with rosiglitazone [33].
Considering the relevance of assessing early signs of the syndrome for disease outcome in
cancer patients, a recent international consensus proposed a definition for cachexia [1], where-
in cancer cachexia comprises a continuum of three clinically relevant stages: pre-cachexia
(early clinical and metabolic signs), cachexia, and refractory or late-stage cachexia (palliative
treatment with a life expectancy less than 3 months). In addition, the importance of early ca-
chexia detection was also addressed (biological signs) and is an important basis for preventive
intervention. Thus, in the following discussion, we consider tumor-bearing rats in such a
classification scheme.
Another important effect of PGZ treatment is body mass preservation, notably during late-
stage of cachexia. Body weight loss is the principal clinical marker of the disease, and a patient
in the refractory phase has a life expectancy of approximately 3 months [1,34]. To the best of
our knowledge, our work is the first to evaluate the effect of PGZ treatment in solid tumor-
bearing rats as a potential approach not only for increasing cachectic animal survival, but also
for attenuating the effects of cachexia. Thus, cachexia induced by Walker 256 tumor, after 14
days, induces 10 to 15% of weight loss (from cachexia to the refractory stage). During the same
period, TP5 animals lost only 3 to 6% (from pre-cachexia to cachexia) of total body weight.
This finding not only demonstrates weight loss attenuation by 40%, but it also demonstrates
delayed onset of the disease. However, despite the important clinical relevance suggested by
our findings, additional studies must be performed for clarification. In addition, we assessed
the impact of PGZ treatment on RPAT, which is the most affected depot during syndrome de-
velopment [10]. The treatment preserved the RPAT mass, at least in a transitory manner, dur-
ing the early stages of the disease. Considering the relevance of WAT as one of the first tissues
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affected by the syndrome and, consequently, its participation in the related metabolic chaos, it
is conceivable that transitory preservation may delay the appearance of cachexia syndrome.
Several studies have addressed the effects of TZD on adipose tissue [11,35,36]. In addition
to its role in adipocyte biology and adipogenesis, in the cachexia stage, PGZ might contribute
to maintaining the adipose mass throughout regulation of the genes related with lipogenesis
control. For this aspect, PGZ was effective at restoring, PPAR-γ, CEBP-α, adiponectin, and
LPL gene expression for RPAT, at least during the early stage (day 7), and therefore, was re-
sponsible for transitory RPAT preservation. We previously demonstrated that these genes are
down-regulated early during cachexia development, which begins day 4 after cell inoculation
[10]. Therefore, no clear information links transitory RPAT preservation and amelioration of
clinical cachexia signs.
Another relevant aspect demonstrated herein is the effect of PGZ on inhibiting tumor mass
growth, which is evident in both the cachexia and refractory stages (day 14 to 26). Interestingly,
it has also been shown that a higher RPAT mass observed on day 7 is negatively related to
tumor growth. In fact, a previous study showed that TZDs exhibit a potential anti-cancerous
effect [19]. However, in cachectic tumor-bearing mice, rosiglitazone treatment that was in-
tended to restore peripheral insulin resistance did not affect tumor mass [20]. Thus, the effect
seems related to the TZD class and dosage, tumor type and cachexia experimental model.
In cachexia induced by Walker tumors, PGZ induced a delay in the appearance of cachexia
signs, with RPAT transient preservation (day 7), and slowed rates of weight loss and tumor
mass growth (day 14 and 26); the latter effect being more pronounced. Additionally, improved
survival in cachectic rats may be due to weight loss prevention, considering that weight loss is
associated with impaired survival in cancer patients. Even considering the short time-course (7
days) of this model, RPATmass maintenance may be clinically relevant because it may be relat-
ed with mass preservation, even for a short time, and may improve anticancer therapy respon-
siveness and tolerability. On the other hand, the magnitude of the tumor mass increase did not
correlate with clinical profile signs; thus, a consistent conclusion on a potential interaction be-
tween body weight preservation and reduced tumor growth is difficult to be proposed based on
the data. Therefore, despite the potential anti-tumor growth effect of PGZ, the evidence for its
related mechanisms is limited.
Anorexia is another prevalent symptom in cachexia and one of the criteria for defining dif-
ferences between cachexia and pre-cachexia. In cachexia induced by the Walker 256 tumor, an-
orexia is evident from the 10th day after cell inoculation. During the period between the 10th
and 14th days, the treatment did not alleviate anorexia. However, in terminal disease, the treat-
ment was effective in alleviating anorexia from the 23rd day. Thus, considering the effect of
PGZ on anorexia, it seems that the early effects demonstrated herein were not consistently cor-
related with anorexia; despite body weight loss attenuation, anorexia did not change. Interest-
ingly, during the late stage, body weight loss attenuation was greater and followed by
amelioration of anorexia. However, determining whether this contributes to survival and the
potential mechanisms requires further investigation.
4.2. Biochemical profile
Hypoglycemia induced by the Walker Tumor 256 has been described in the literature [37], and
even though both groups have demonstrated this effect, PGZ treatment partially improved fast-
ing glycemia during cachexia development. This effect on cachexia-induced hypoglycemia was
demonstrated in tumor-bearing animals treated with TZDs [11]. In addition, we demonstrate
that the treatment exhibits effects on day 7 (early stage). In fact, this benefit has been described
as the result of multiple metabolic changes, including an increase in and/or restoration of
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glucose uptake and metabolism by muscle cells, an increase in fat mass, reduced lipolysis in the
tissue, and diminished glucose release by the liver [38,39]. However, additional studies are nec-
essary to assess the potential mechanisms involved in restoring glycaemia and the potential
consequences for managing reduced body fat and tumor growth.
A high concentration of triglycerides (TAG) and total cholesterol are the most common
lipid abnormalities in patients with insulin resistance, which is also a condition that oncologic
patients present and is evident in certain cancer types [40,41], and in animals with tumor-
induced cachexia [42]. Cachexia-induced changes in TAG plasma concentration were not
reversed with PGZ treatment. In tumor-induced cachexia animal models, dyslipidemia is de-
scribed from the 8th day after tumor cell inoculation [42]. In this respect, it is worth noting that
the treatment did not affect the cachexia-induced TAG level changes. Furthermore, this alter-
ation is not associated with anorexia, which is present in this animal model, typically beginning
the 10th day after tumor cells inoculation [10].
Considering that PGZ treatment eventually induces liver toxicity, we measured serum trans-
aminases levels [43] (AST, ALT) and albumin concentration on the 7th and 14th days. Although
both enzymes exhibited changes on the 14th day (cachexia stage), with no effect from PGZ,
AST concentration was high at both times (days 7 and 14). However, in response to both ca-
chexia and PGZ, ALT concentration did not exhibit relevant changes on day 7 (early stage).
Biochemical data analyses demonstrated that the treatment is relatively safe, particularly dur-
ing the initial stages of cachexia. However, even considering the beneficial effect on fasting
glycaemia, hepatotoxicity should be considered when evaluating PGZ treatment as potential
anti-cachectic therapeutic approach.
4.3. Glucose uptake from isolated adipocytes
Disrupted energy homeostasis seems to be a main target for generating the metabolic “chaos”
established during the cachexia syndrome [40,41]. Changes in carbohydrate, lipid and protein
metabolism have been described both in cachectic patients [39,44] and tumor-bearing animals
[9,10,27]. Glucose metabolism abnormalities have similarly been described, such as glucose in-
tolerance, increased hepatic production (gluconeogenesis) and recycling of glucose carbons,
hypoglycemia, hypoinsulinemia and resistance to peripheral insulin resistance [37,39,45]. Fur-
thermore, the 256 Walker tumor is an avid glucose consumer [46]; thus, it is a major source for
ATP and lactic acid generation through glycolysis, which stimulates hepatic gluconeogenesis
[37]. Despite the importance of glucose in adipose tissue metabolism, as far as we know, this is
the first study that has evaluated glucose uptake (3H 2-deoxy-D-Glucose) during early-stage ca-
chexia. Considering this aspect, isolated RPAT adipocytes in cachectic rats exhibited lower
insulin-stimulated glucose uptake, which was fully restored in the TP5 adipocytes. Our previ-
ous studies showed that the RPAT undergoes a profound mass reduction due to cachexia. In
addition, its mass decreases the most compared with other visceral adipose tissue depots [10].
Further, the genes related to AT development (PPARγ and CEBPα) were down-regulated on
day 4 after tumor cell inoculation (very early stage) [10]. This change may be important to the
RPAT capacity to store TAG and, consequently, impair maintenance of its tissue mass.
As previously described, PGZ treatment transiently preserved RPAT mass during early-
stage cachexia. In addition, despite the reduced glucose uptake in cachectic animals, the treat-
ment was effective in restoring insulin sensitivity in adipocytes isolated from RPAT. Glucose is
a major substrate for TAG formation, because hexose retained by the adipocyte can be incorpo-
rated into both the fatty acid (de novo lipogenesis) and glycerol molecule moieties of TAG. Ad-
ditionally, its full oxidation provides energy for maintaining endergonic processes, such as
lipogenesis; this effect may contribute to the enhanced RPAT preservation, glucose metabolism
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maintenance and consequent delay of the initial alterations that establish the syndrome, partic-
ularly the alterations that affect fat depots.
In fact, well-described TZD effects include insulin sensitization and the promotion of fatty
acid storage by adipose tissue [47]. TZDs promote the appearance of new fat cells that are
smaller and more insulin-sensitive, which yield greater insulin-dependent glucose uptake and
greater TAG synthesis [13]. Evidence suggests that TZDs, through PPARγ activation, directly
modulate the insulin transduction pathway in adipose tissue [48], which regulates expression
of various genes involved in glucose metabolism, such as GLUT 1 (constitutive) and GLUT 4
(sensitive to insulin) [47]. However, although PGZ treatment improved glucose uptake in iso-
lated adipocytes from cachectic rats, the mechanisms involved remain unknown.
Conclusion
The results demonstrate that treatment with 5 mg/kg of PGZ delayed the onset of cachexia
clinical signs, followed by an increase in cachectic rat survival, suggesting a potential anti-
cachectic effect. PGZ treatment was effective during the early stages of the disease, which was
demonstrated by transient adipose tissue mass preservation and insulin-sensitivity restoration
in adipocytes. Furthermore, the relationship between greater RPAT mass induced by PGZ and
reduced weight loss corroborates the hypothesis that preserving WAT may slow cachexia de-
velopment. At late-stage cachexia, weight loss and anorexia were attenuated. Finally, in addi-
tion to the TZD anti-tumor properties, a potential anti-cachectic effect with eventual potential
in the therapeutic treatment of the syndrome is proposed.
Acknowledgments
The authors thank Dr. Paulo S Alcântara, M.D., Ph.D., Department of Surgical Technology,
University of São Paulo, for academic advice about treatment with PGZ. We thank Romy
Rochfield for excellent assistance in the review of English.
Author Contributions
Conceived and designed the experiments: MB SP RS RN CS SF MS FL MLBJr. Performed the
experiments: MB FH RS FF KS PK SA RN. Analyzed the data: MB SP CS SF FL MLBJr. Con-
tributed reagents/materials/analysis tools: RN CS FL. Wrote the paper: MB SP SF MS FL
MLBJr.
References
1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, et al. Definition and classification of cancer ca-
chexia: an international consensus. Lancet Oncol. 2011; 12: 489–495. doi: 10.1016/S1470-2045(10)
70218-7 PMID: 21296615
2. Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. Body composition, symptoms, and survival
in advanced cancer patients referred to a phase I service. PLoS ONE. 2012; 7: e29330. doi: 10.1371/
journal.pone.0029330 PMID: 22235285
3. Palesty JA, Dudrick SJ. What we have learned about cachexia in gastrointestinal cancer. Dig Dis.
2003; 21: 198–213. PMID: 14571093
4. Dahlman I, Mejhert N, Linder K, Agustsson T, Mutch DM, et al. Adipose tissue pathways involved in
weight loss of cancer cachexia. Br J Cancer. 2010; 102: 1541–1548. doi: 10.1038/sj.bjc.6605665
PMID: 20407445
5. Arner P. Medicine. Lipases in cachexia. Science. 2011; 333: 163–164. doi: 10.1126/science.1209418
PMID: 21737725
6. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, et al. Body composition and time course
changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative
care—correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;
103: 2189–2198. PMID: 15822132
Anti-Cachectic Effect of Pioglitazone
PLOS ONE | DOI:10.1371/journal.pone.0122660 March 25, 2015 14 / 16
7. Ryden M, Agustsson T, Laurencikiene J, Britton T, Sjolin E, et al. Lipolysis—not inflammation, cell
death, or lipogenesis—is involved in adipose tissue loss in cancer cachexia. Cancer. 2008; 113:
1695–1704. doi: 10.1002/cncr.23802 PMID: 18704987
8. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009; 89: 381–410. doi: 10.1152/physrev.
00016.2008 PMID: 19342610
9. Bing C, Russell S, Becket E, Pope M, Tisdale MJ, et al. Adipose atrophy in cancer cachexia: morpho-
logic and molecular analysis of adipose tissue in tumour-bearing mice. Br J Cancer. 2006; 95:
1028–1037. PMID: 17047651
10. Batista ML Jr, Neves RX, Peres SB, Yamashita AS, Shida CS, et al. Heterogeneous time-dependent
response of adipose tissue during the development of cancer cachexia. J Endocrinol. 2012; 215:
363–373. doi: 10.1530/JOE-12-0307 PMID: 23033362
11. Asp ML, Tian M, Wendel AA, Belury MA. Evidence for the contribution of insulin resistance to the devel-
opment of cachexia in tumor-bearing mice. Int J Cancer. 2010; 126: 756–763. doi: 10.1002/ijc.24784
PMID: 19634137
12. Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol
Metab. 2000; 11: 362–368. PMID: 11042466
13. Sharma S, Sowjanya A, Kumari M, Suryaprakash R, Cynthia G, et al. Biochemical mechanism of insulin
sensitization, lipid modulation and anti-atherogenic potential of PPAR α/γ dual agonist: Ragaglitazar.
Life Sci. 2006; 80: 235–244. PMID: 17014868
14. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, et al. Ligands for peroxisome proliferator-
activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human
breast cancer cells in vitro and in BNXmice. Proc Natl Acad Sci U S A. 1998; 95: 8806–8811. PMID:
9671760
15. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 2003;
9: 1–9. PMID: 12538445
16. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, et al. Terminal differentiation of human lipo-
sarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid
X receptor. Proc Natl Acad Sci U S A. 1997; 94: 237–241. PMID: 8990192
17. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, et al. Induction of solid tumor differentiation
by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposar-
coma. Proc Natl Acad Sci U S A. 1999; 96: 3951–3956. PMID: 10097144
18. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, MidathadaMV, et al. Thiazolidinediones
and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007; 25:
1476–1481. PMID: 17442990
19. Saha S, Chan DS, Lee CY, WongW, New LS, et al. Pyrrolidinediones reduce the toxicity of thiazolidine-
diones and modify their anti-diabetic and anti-cancer properties. Eur J Pharmacol. 2012; 697: 13–23.
doi: 10.1016/j.ejphar.2012.09.021 PMID: 23041271
20. Asp ML, Tian M, Kliewer KL, Belury MA. Rosiglitazone delayed weight loss and anorexia while attenu-
ating adipose depletion in mice with cancer cachexia. Cancer Biol Ther. 2011; 12: 957–965. doi: 10.
4161/cbt.12.11.18134 PMID: 22104958
21. Seelaender MC, Nascimento CM, Curi R, Williams JF. Studies on the lipid metabolism of Walker 256
tumour-bearing rats during the development of cancer cachexia. BiochemMol Biol Int. 1996; 39:
1037–1047. PMID: 8866022
22. Machado A, Costa Rosa LPB, Seelaender ML. Adipose tissue in Walker 256 tumour-induced cachexia:
possible association between decreased leptin concentration and mononuclear cell infiltration. Cell and
Tissue Research. 2004; 318: 503–514. PMID: 15490241
23. Bennani-Baiti N, Walsh D. Animal models of the cancer anorexia-cachexia syndrome. Support Care
Cancer. 2011; 19: 1451–1463. doi: 10.1007/s00520-010-0972-0 PMID: 20714754
24. Rodbell M. Metabolism of Isolated Fat Cells. I. Effects of Hormones on Glucose Metabolism and Lipoly-
sis. J Biol Chem. 1964; 239: 375–380. PMID: 14169133
25. DiGirolamoM, Fine JB. Cellularity measurements. Methods Mol Biol. 2001; 155: 65–75. PMID:
11293084
26. Lima FB, Machado UF, Bartol I, Seraphim PM, Sumida DH, et al. Pinealectomy causes glucose
intolerance and decreases adipose cell responsiveness to insulin in rats. Am J Physiol. 1998; 275:
E934–941. PMID: 9843734
27. Das SK, Eder S, Schauer S, Diwoky C, Temmel H, et al. Adipose triglyceride lipase contributes to cancer-
associated cachexia. Science. 2011; 333: 233–238. doi: 10.1126/science.1198973 PMID: 21680814
28. Chilcott J, Tappenden P, JonesML,Wight JP. A systematic review of the clinical effectiveness of pioglitazone
in the treatment of type 2 diabetesmellitus. Clinical Therapeutics. 2001; 23: 1792–1823. PMID: 11768834
Anti-Cachectic Effect of Pioglitazone
PLOS ONE | DOI:10.1371/journal.pone.0122660 March 25, 2015 15 / 16
29. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Medicine. 1999; 16: 179–192.
PMID: 10227562
30. TangWH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione thera-
py in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003; 41: 1394–1398.
PMID: 12706937
31. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients
with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007; 298: 1180–1188.
PMID: 17848652
32. el-Kebbi IM, Roser S, Pollet RJ. Regulation of glucose transport by pioglitazone in cultured muscle
cells. Metabolism. 1994; 43: 953–958. PMID: 8052151
33. Yang K-J, Noh J-R, Kim Y-H, Gang G-T, Hwang J-H, et al. Differential modulatory effects of rosiglita-
zone and pioglitazone on white adipose tissue in db/db mice. Life Sci. 2010; 87: 405–410. doi: 10.
1016/j.lfs.2010.08.002 PMID: 20723549
34. Argiles JM, Anker SD, EvansWJ, Morley JE, Fearon KC, et al. Consensus on cachexia definitions.
J AmMed Dir Assoc. 2010; 11: 229–230. doi: 10.1016/j.jamda.2010.02.004 PMID: 20439040
35. Dubuisson O, Dhurandhar EJ, Krishnapuram R, Kirk-Ballard H, Gupta AK, et al. PPARgamma-
independent increase in glucose uptake and adiponectin abundance in fat cells. Endocrinology. 2011;
152: 3648–3660. doi: 10.1210/en.2011-0225 PMID: 21791563
36. Li P, FanW, Xu J, Lu M, Yamamoto H, et al. Adipocyte NCoR knockout decreases PPARgamma phos-
phorylation and enhances PPARgamma activity and insulin sensitivity. Cell. 2011; 147: 815–826. doi:
10.1016/j.cell.2011.09.050 PMID: 22078880
37. Fernandes LC, Machado UF, Nogueira CR, Carpinelli AR, Curi R. Insulin secretion in Walker 256 tumor
cachexia. Am J Physiol. 1990; 258: E1033–1036. PMID: 2193528
38. Burkey BF, Dong M, Gagen K, Eckhardt M, Dragonas N, et al. Effects of pioglitazone on promoting en-
ergy storage, not expenditure, in brown adipose tissue of obese fa/fa zucker rats: comparison to cl
316,243. Metabolism. 2000; 49: 1301–1308. PMID: 11079820
39. Honors MA, Kinzig KP. The role of insulin resistance in the development of muscle wasting during can-
cer cachexia. J Cachexia Sarcopenia Muscle. 2012; 3: 5–11. doi: 10.1007/s13539-011-0051-5 PMID:
22450024
40. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010; 26: 146–151. doi: 10.1097/MOG.
0b013e3283347e77 PMID: 19918173
41. Das SK, Hoefler G. The role of triglyceride lipases in cancer associated cachexia. Trends Mol Med.
2013; 19: 292–301. doi: 10.1016/j.molmed.2013.02.006 PMID: 23499576
42. Cassolla P, Moreira CC, Liboni TF, Zaia CT, Borba-Murad GR, et al. Changes in blood metabolic pa-
rameters during the development of Walker-256 tumour-induced cachexia in rats are not caused by de-
creased food intake. Cell Biochem Funct. 2012; 30: 265–270. doi: 10.1002/cbf.2792 PMID: 22179849
43. Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients
with normal and elevated baseline liver enzymes. Am J Gastroenterol. 2005; 100: 1317–1321. PMID:
15929763
44. Batista ML Jr., Olivan M, Alcantara PS, Sandoval R, Peres SB, et al. Adipose tissue-derived factors as
potential biomarkers in cachectic cancer patients. Cytokine. 2013; 61: 532–539. doi: 10.1016/j.cyto.
2012.10.023 PMID: 23200412
45. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am
Coll Nutr. 1992; 11: 445–456. PMID: 1506607
46. Vaupel P, Okunieff P, Neuringer LJ. Blood flow, tissue oxygenation, pH distribution, and energy metab-
olism of murine mammary adenocarcinomas during growth. Adv Exp Med Biol. 1989; 248: 835–845.
PMID: 2782192
47. Shoelson SE, Herrero L, Naaz A. Obesity, Inflammation, and Insulin Resistance. Gastroenterology.
2007; 132: 2169–2180. PMID: 17498510
48. Gurnell M. 'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel In-
sights from Human Genetic Studies. PPAR Res. 2007; 2007: 83593. PMID: 17389771
Anti-Cachectic Effect of Pioglitazone
PLOS ONE | DOI:10.1371/journal.pone.0122660 March 25, 2015 16 / 16
